2[1]Faredj, Walenga JM, Hoppensteadt D, et al. Comparative study on the in vitro and in vivo studise of seven low-molecular weight heparins. Haemostasis,1998,8:3～9.
5[5]Fareed J, Walenga J, Hoppensteadt D, et al. Chemleal and biological hererogeneity in low molecular weight heparins; implication for clinical use and seandrdization. Semin Thromb Hemost, 1989,15:440 ～ 444.
6[6]Melissari E, Parker CJ, Wilson NV, et al. Use of LMWH in pregnancy.Thromb Haemost, 1992,68:652 ～ 656.
7[7]Salznan EW, Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest, 1980,65:64～ 68.
8[8]Blajchman MA, Young E. Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and LMWH on vessel wall permeability in rabbits. Ann N Y Acad Sci, 1989,556:246 ～ 250.
9[9]Key R, Wongks, YU. Low molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med, 1995,333(24):1588 ～ 1594.
10[15]Green D, Hims J, Prins MH, et al. LMWH: a critical analysis of clinical trials. Pharmacol Rev, 1994,46:89 ～ 96.
